Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Live Oak Private Wealth LLC

Live Oak Private Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,871 shares of the medical research company's stock after buying an additional 1,176 shares during the period. Live Oak Private Wealth LLC's holdings in Thermo Fisher Scientific were worth $4,912,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth $25,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $30,000. Finally, Noble Wealth Management PBC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $35,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.6%

Shares of NYSE TMO traded up $2.38 during midday trading on Monday, reaching $400.26. 2,485,958 shares of the company's stock were exchanged, compared to its average volume of 1,944,901. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock has a market capitalization of $151.09 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The business's fifty day moving average price is $411.66 and its two-hundred day moving average price is $486.42.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the company earned $5.11 earnings per share. The company's revenue for the quarter was up .2% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on TMO. Royal Bank Of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Finally, Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.